natgillin/translations-raw huggingface dataset:
Regular full blood counts, including neutrophil and platelet counts, should be performed during MabThera therapy.
Tijekom terapije lijekom MabThera potrebno je redovito kontrolirati kompletnu krvnu sliku, uključujući broj neutrofila i trombocita.
regular monitoring of haemoglobin levels;
redovitim praćenjem razina hemoglobina;
Regular monitoring of liver function is recommended during dinutuximab immunotherapy.
Preporučuje se redovito praćenje funkcije jetre tijekom imunoterapije dinutuksimabom.
regular monitoring of liver function; the importance of telling patients to report immediately any possible pregnancy that occurs during Opsumit use.
redovitim praćenjem funkcije jetre; važnost upućivanja bolesnice da prijavi svaku moguću trudnoću do koje dođe tijekom primjene lijeka Opsumit.
Regular monitoring of the coagulation profile is necessary.
Nužno je redovito praćenje koagulacijskog profila.
Regular monitoring of the response to FSH-treatment helps to prevent ovarian overstimulation.
 Redovito praćenje odgovora na liječenje FSH-om pridonosi sprječavanju pretjerane stimulacije jajnika.
Regular monthly treatments with Comfortis break the fleas’ life cycle and may be needed to control the flea population in contaminated households.
Redovno mjesečno tretiranje Comfortisom prekida životni ciklus buha i može biti potrebno radi kontrole populacije buha u kontaminiranim kućanstvima.
Regular monthly treatments with the insecticidal active substance in this product (spinosad) break the fleas’ life cycle and may be used to control the flea population in contaminated households.
Redovno mjesečno liječenje insekticidnom djelatnom tvari spinosad, prekida životni ciklus buha i može se upotrijebiti u kontroli populacije buha u kontaminiranim kućanstvima.
Regular monthly treatments with the insecticidal active substance, spinosad, break the fleas’ life cycle and may be used to control the flea population in contaminated households.
Redovno mjesečno liječenje insekticidnom djelatnom tvari spinosad, prekida životni ciklus buha i može se upotrijebiti za kontrolu populacije buha u kontaminiranim kućanstvima.
Regular ophthalmological examinations should be conducted in these patients to detect macular oedema.
Treba obavljati redovite oftalmološke preglede u tih bolesnika, kako bi se mogao uočiti makularni edem.
Regular review of patients as treatment is stepped down is important.
Važno je provoditi redovite preglede bolesnika kod smanjivanja doze.
Regular review of the administration by the patient and/or caregiver needs to be performed to ensure maintenance of optimal practice.
Ako lijek primjenjuje bolesnik ili njegovatelj, primjenu treba redovito provjeravati kako bi se osiguralo održavanje optimalne razine liječenja.
Regular review of your/your carer’s injection technique will be performed to ensure continued appropriate handling.
Vaša tehnika davanja injekcije ili tehnika Vašeg skrbnika redovito će se provjeravati kako bi se osiguralo stalno ispravno rukovanje lijekom.
Regular urine analyses should be performed to monitor this event.
Potrebno je redovito raditi analizu mokraće zbog praćenja ove promjene.
Regular use of Bretaris Genuair can help you when you have ongoing shortness of breath related to your disease and will help you to minimise the effects of the disease on your everyday life.
Redovito uzimanje lijeka Bretaris Genuair može Vam pomoći kad osjećate nedostatak zraka povezan s bolešću te će pomoći u smanjenju utjecaja bolesti na svakodnevni život.
Regular use of Eklira Genuair can help you when you have ongoing shortness of breath related to your disease and will help you to minimise the effects of the disease on your everyday life.
Redovito uzimanje lijeka Eklira Genuair može Vam pomoći kad osjećate nedostatak zraka povezan s bolešću te će pomoći u smanjenju utjecaja bolesti na svakodnevni život.
regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes
pravilnim kontrakcijama maternice u trajanju od najmanje 30 sekundi i frekvencijom od ≥ 4 u 30 minuta
regular uterine contractions of at least 30 seconds duration at a rate of  4 per 30 minutes
pravilnim kontrakcijama maternice u trajanju od najmanje 30 sekundi i frekvencijom od  4 u 30 minuta
Regularly during your treatment and up to 6 months after your treatment, your doctor needs to check your skin for a type of cancer called “cutaneous squamous cell carcinoma”.
Redovito tijekom liječenja i do 6 mjeseci nakon završetka liječenja liječnik Vam mora pregledavati kožu zbog moguće pojave jedne vrste raka kože koji se zove "planocelularni karcinom kože".
Regurgitation
vraćanje kiselog sadržaja iz želuca
regurgitation (bringing food back up)
regurgitacija (vraćanje hrane)
regurgitation, increase in stomach aspirate
regurgitacija (vraćanje hrane iz želuca), povećanje učestalosti udisaja želučanog sadržaja,
Regurgitation, increased gastric aspirate, necrotising enterocolitis
regurgitacija, povećani želučani aspirat, nekrotizirajući enterokolitis
Reinfarction
Ponovni infarkt
Reinforced monitoring of the
Preporučuje se pojačano praćenje
Reinitiate treatment with Nplate in accordance with dosing and administration recommendations (see sections 4.2 and 4.4).
Ponovno započinjanje liječenja Nplateom treba biti prema uputama o doziranju i primjeni (vidjeti dio 4.2 i 4.4).
Reinitiate treatment with Nplate in accordance with dosing and administration recommendations.
Ponovno započinjanje liječenja Nplateom treba biti prema uputama o doziranju i primjeni.
Reintroduction of Jentadueto should then be discussed taking into account the benefit/risk ratio in an individual basis as well as renal function.
Potom treba raspraviti ponovnouvođenje Jentadueta uzimajući u obzir omjer koristi i rizika za pojedinog bolesnika, kao i funkciju bubrega.
rejection of transplanted bone marrow (graft versus host disease)
odbacivanje presađene koštane srži (bolest presatka protiv primatelja)
rejection of transplanted bone marrow (graft versus host disease)
odbacivanje transplantirane koštane srži (bolest presatka protiv primatelja)
rejection of transplanted bone marrow;
odbacivanje presađene koštane srži;
Rejection response to blood transfusions.
reakcija odbacivanja na transfuzije krvi
Relapse
0 (0/9)
Relapse
6/205
Relapse
64% (38/59)
Relapse
ispitivanje)
Relapse
liječenja Relaps
Relapse % (n/N)
Relaps % (n/N)
Relapse %(n/N)
Relaps % (n/N)
Relapse %, (n/N)
Relaps %, (n/N)
Relapse includes observations through follow-up Week 24.
Relaps obuhvaća opažanja do kraja 24. tjedna praćenja.
Relapse Rate1
Stopa relapsa1
Relapse was defined as haematological relapse (blasts in bone marrow greater than 5% following CR) or an extramedullary relapse.
Recidiv je definiran kao hematološki recidiv (blasti u koštanoj srži veći od 5% nakon CR-a) ili ekstramedularni recidiv.
Relapse*
Relaps
Relapse**
Relaps
Relapse** %(n/N)
Relaps** %(n/N)
Relapse** %, (n/N)
Relaps** %, (n/N)
Relapse-free week 108
Bez relapsa 108. tjedan
Relapse5-free survival (RFS) for CR/CRh*
Preživljenje bez recidiva5 za CR/CRh
Relapseb
SVR
Relapsec
Relapsc
Relapsed Ovarian Cancer
Recidiv karcinoma jajnika
Relapsed SCLC
Recidiv karcinoma pluća malih stanica
Relapsed/refractory follicular lymphoma
Relapsirajući/refraktorni folikularni limfom
Relapser
Relaps
relapsers
95,9; 100,0
relapsers
pegIFN/RBV
relapsers Outcome for subjects without SVR12
Virološki neuspjeh
Relapsers† in the parent study (29)
Bolesnici koji su doživjeli relaps u izvornom ispitivanju (29)
Relapses in previous 12 months, median (range)
Medijan broja relapsa u prethodnih 12 mjeseci (raspon)
Relapse†
Relaps
Relapse† %(n/N)
Relaps† % (n/N)
Relapsing
Relaps
Relapsing means that the patient has flare-ups of the symptoms.
„Relaps” znači da dolazi do izbijanja simptoma kod bolesnika.
Relapsing- Remitting Multiple Sclerosis
Relapsno remitirajuća multipla skleroza
Relapsing- Remitting Multiple Sclerosis
Relapsno- remitirajuća multipla skleroza
Relapsing-remitting multiple sclerosis
Relapsno remitirajuća multipla skleroza
related adverse events, the
događaja povezanog s bedakilinom,
related adverse events, the
intervala povezanog s DM-6705,
Related adverse reactions of CTC grade 3 and 4 occurred in 37% of patients in clinical trials.
Povezane nuspojave CTC stupnja 3 ili 4 pojavile su se u 37% ispitanika u kliničkim ispitivanjima.
related AIS
HPV 16/18
related AIS
povezan s HPV-om
related CIN 3
povezan s HPV 16/18
related CIN 3
povezan s HPV-om
related death
Ponavljajući
Related discontinuations
Povezana ukidanja liječenja
relationship of ivabradine in paediatric chronic heart failure patients aged 6 months to less than 18 years is similar to the PK/PD relationship described in adults.
PK/PD odnos ivabradina u pedijatrijskih bolesnika koji boluju od kroničnog zatajenja srca starosti od 6 do 18 mjeseci sličan je PK/PD odnosu opisanom u odraslih.
Relative % predicted
Procijenjeni relativni
Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
Relativno velika predoziranja (200 mg, odnosno, 105 mg/dan tijekom 3 dana) povezana su ili samo sa simptomima umora, slabosti i/ili proljeva, ili ni s kakvim simptoma.
Relative mean change (%)
Relativna srednja promjena (%)
Relative overdosing could occur in patients with moderate renal impairment.
U bolesnika s umjerenim oštećenjem funkcije bubrega može doći do relativnog predoziranja.
Relative potency (ELISA test) by comparison with a reference vaccine
Relativna potentnost (ELISA test) u usporedbi s referentnim cjepivom
Relative potency (ELISA test) by comparison with a reference vaccine.
Relativna potencija (ELISA test) u usporedbi s referentnim cjepivom.
Relative rate reduction(1)
Relativna stopa smanjenja(1)
Relative Risk
Relativan rizik
Relative Risk (95% C.I.)
Relativni rizik
Relative risk (95% CI)
Relativan rizik (95% CI)
Relative Risk (95% CI)
Relativan rizik (95% interval pouzdanosti)
Relative Risk (95% CI) of GvHD and TRM
Relativni rizik (95 % CI) od reakcije presatka protiv primatelja (GvHD) i smrtnosti povezane s liječenjem (TRM)
Relative risk (95% CI) of GvHD and TRM
Relativni rizik (95% CI) za GvHD i TRM
Relative risk reduction
Relativno smanje- nje rizika
Relative risk reduction
Smanjenje relativnog rizika
Relative Risk Reduction (97.5% CI)
Smanjenje relativnog rizika (97,5% CI)
Relative to fasting conditions, administration of an early capsule formulation of idelalisib with a high- fat meal resulted in no change in Cmax and a 36% increase in mean AUCinf.
U usporedbi s primjenom natašte, primjena idelalisiba u kapsuli formuliranoj u ranoj fazi razvoja lijeka s obrokom bogatim mastima nije uzrokovala promjene u Cmax, a srednja vrijednost AUCinf porasla je za 36%.
Relative to fasting conditions, the administration of a single dose of elbasvir/grazoprevir with a high- fat (900 kcal, 500 kcal from fat) meal to healthy subjects resulted in decreases in elbasvir AUC0-inf and Cmax of approximately 11 % and 15 %, respectively, and increases in grazoprevir AUC0-inf and Cmax of approximately 1.5-fold and 2.8-fold, respectively.
U odnosu na primjenu natašte, primjena jednokratne doze elbasvira/grazoprevira uz obrok s visokim udjelom masti (900 kcal, 500 kcal iz masti) u zdravih ispitanika snizila je AUC0-inf i Cmax elbasvira za približno 11% odnosno 15% te povisila AUC0-inf i Cmax grazoprevira za približno 1,5 puta odnosno 2,8 puta.
Relative to fasting conditions, the administration of Genvoya with a light meal (~400 kcal, 20% fat) or high-fat meal (~800 kcal, 50% fat) did not affect overall exposures of tenofovir alafenamide to a clinically meaningful extent (approximately 15% and 18% higher AUC with a light or high-fat meal, respectively, versus fasted).
U odnosu na stanje natašte, primjena lijeka Genvoya s laganim obrokom (400 kcal, 20%masnoće) ili visokomasnim obrokom (800 kcal, 50% masnoće) nije utjecala na ukupne izloženosti tenofoviralafenamidu u klinički značajnoj mjeri (otprilike 15% i 18% veći AUC uz lagani ili visokomasni obrok u odnosu na stanje natašte).
Relative to fasting conditions, the administration of Stribild with a light meal (~373 kcal, 20% fat) or high-fat meal (~800 kcal, 50% fat) resulted in increased exposures of elvitegravir and tenofovir.
U odnosu na natašte, primjena Stribilda s laganim obrokom (~373 kcal, 20% masnoće) ili visokomasnim obrokom (~800 kcal, 50% masnoće) rezultirala je povećanom izlošenošću elvitegravira i tenofovira.
Relative to healthy subjects (n = 331), velpatasvir AUC0-24 and Cmax were 37% lower and 41% lower, respectively in HCV-infected patients.
U odnosu na one u zdravih ispitanika (n = 331), AUC0-24 i Cmax velpatasvira u bolesnika zaraženih HCV-om iznosile su 37 % manje odnosno 41 % manje.
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).
U odnosu na monoterapiju nivolumabom, produljenje preživljenja bez progresije bolesti (engl. progression-free survival, PFS) uz liječenje kombinacijom nivolumaba i ipilimumaba ustanovljeno je samo u bolesnika s niskom razinom tumorske ekspresije PD-L1 (vidjeti dijelove 4.4 i 5.1).
Relative to non-obese subjects daptomycin systemic exposure measured by AUC was about 28% higher in moderately obese subjects (Body Mass Index of 25-40 kg/m2) and 42% higher in extremely obese subjects (Body Mass Index of > 40 kg/m2).
U usporedbi s ispitanicima koji nisu bili pretili, sustavna izloženost daptomicinu, mjerena pomoću AUC, bila je za oko 28% veća u umjereno pretilih ispitanika (indeks tjelesne mase 25-40 kg/m2) a 42% veća u ekstremno pretilih ispitanika (indeks tjelesne mase >40 kg/m2).
Relative to placebo, the decline in quality of life was slower for Xofigo during the on-treatment period as measured by EQ-5D utility index score (-0.040 versus – 0.109; p=0.001), EQ-5D self-reported Visual Analogue health status scores (VAS) (-2.661 versus -5.860; p=0.018) and the FACT P total score (-3.880 versus -7.651, p=0.006) but did not reach published minimally important differences.
U odnosu na placebo, smanjenje kvalitete života bilo je sporije za Xofigo tijekom perioda primjene lijeka, mjereno EQ 5D indeksom korisnosti (-0,040 naprama -0,109; p=0,001), EQ 5D prijavljenim rezultatima na vizualnoj analognoj ljestvici (VAS) samoprocjene zdravstvenog stanja (-2,661 naprama -5,860; p=0,018) i FACT P ukupnim rezultatom (-3,880 naprema -7,651, p=0,006), ali nije doseglo objavljene minimalne važne razlike.
Relative to subjects with normal renal function, velpatasvir AUCinf was 50% higher in subjects with severe renal impairment (see section 4.2).
U odnosu na ispitanike s normalnom bubrežnom funkcijom, AUCinf velpatasvira bio je 50 % viši u ispitanika s teškim oštećenjem bubrega (vidjeti dio 4.2).
Relative to the adverse reactions noted in section b.
U odnosu na nuspojave navedene u dijelu b.
Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4 % and 23 %, respectively.
U odnosu na AUC temozolomida izloženost MTIC-u iznosi ~2,4 %, a izloženost AIC-u 23 %.
Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4 % and 23 %, respectively.
U odnosu na AUC TMZ-a izloženost MTIC-u iznosi ~2,4 %, a izloženost AIC-u 23 %.
Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4% and 23%, respectively.
U odnosu na AUC temozolomida izloženost MTIC-u iznosi ~2,4%, a izloženost AIC-u 23%.
Relative to the pathology status of lymph node collection from a complete lymph node dissection, technetium Tc 99m tilmanocept correctly localised in sentinel lymph nodes predictive of harbouring metastatic tumour in 38 of 39 patients, for a false negative rate of 2.56%.
U odnosu na patološki status skupine limfnih čvorova dobivenih potpunom disekcijom limfnih čvorova, tilmanocept obilježen radioaktivnim tehnecijem Tc 99m točno je lokaliziran u limfnim čvorovima čuvarima koji ukazuju na metastatski tumor u 38 od 39 bolesnika, s postotkom lažno negativnog rezultata od 2,56%.
relatively few platelets in blood (thrombocytopenia), low white blood cell count (leukopenia), destruction of red blood cells (haemolysis), low blood pressure
relativno mali broj krvnih pločica u krvi (trombocitopenija), nizak broj bijelih krvnih stanica (leukopenija), raspadanje crvenih krvnih stanica (hemoliza), nizak krvni tlak
RELEASE
kože.
RELEASE
OTPUSTITE
release (ER) /bupropion ER on the occurrence of major adverse cardiovascular
pojavu velikih štetnih kardiovaskularnih događaja (engl. major adverse
Release button
Otpustite gumb
Release liner
Zaštitni sloj
Release liner Polyester
Zaštitna folija: poliester
Release liner: polyester film, fluoropolymer-coated.
Zaštitni sloj: poliesterski film, obložen fluoropolimerom.
Release liner: Transparent fluoropolymer coated polyester film.
Zaštitni sloj: poliesterski film obložen prozirnim fluoropolimerom.
Release residual air (prime the pen)
Oslobodite zaostali zrak
Release the dose setting knob.
Otpustite gumb za podešavanje doze.
RELEASE the green button
OTPUSTITE zeleni gumb
RELEASE the orange button
OTPUSTITE narančasti gumb
Release the plunger.
Otpustite klip.
Release the skin fold and gently pull the needle out.
Otpustite nabor kože i lagano izvucite iglu
release the skin use this free hand to hold on to the main part of the syringe – this will help steady it and stop it from moving.
pustite kožni nabor tom slobodnom rukom prihvatite glavni dio štrcaljke - tako ćete je umiriti i spriječiti pomicanje.
Release the skin with the first hand
Pustite kožu iz ruke kojom ju držite
Release the skin with the first hand.
Pustite kožu iz ruke.
Release your thumb from the plunger
Maknite palac s klipa.
Releasing an egg too early (premature ovulation)
preuranjeno oslobađanje oocite (preuranjena ovulacija)
relevance of the
značajnost smanjenja C8h
relevant (as
značajne (prema
Relevant data is included in the Summary of Product Characteristics of the labelled medicinal products.
Relevantni podaci navedeni su u Sažetku opisa svojstava obilježenih lijekova.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii).
Značajni primjeri su retinitis izazvan citomegalovirusom, generalizirane i/ili fokalne infekcije mikobakterijama i pneumonija izazvana s Pneumocystis jiroveci (otprije poznatim kao Pneumocystis carinii).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumonia caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii).
Relevantni primjeri su citomegalovirusni retinitis, generalizirane i/ili fokalne mikobakterijske infekcije i pneumonija koju uzrokuje Pneumocystis jirovecii (prije poznata kao Pneumocystis carinii).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Relevantni primjeri su citomegalovirusni retinitis, generalizirane i/ili fokalne mikobakterijske infekcije i upala pluća prouzročena s Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Relevantni primjeri su retinitis izazvan citomegalovirusom, generalizirane i/ili žarišne mikobakterijske infekcije i pneumonija čiji je uzročnik Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Relevantni primjeri uključuju citomegalovirusom izazvani retinitis, generalizirane i/ili fokalne infekcije mikobakterijama i pneumoniju izazvanu s Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Važni primjeri su citomegalovirusni retinitis, generalizirane i/ili fokalne mikobakterijske infekcije i upala pluća prouzročena gljivicom Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jiroveci pneumonia.
Mjerodavni primjeri su citomegalovirusni retinitis, generalizirane i/ili fokalne mikobakterijske infekcije i pneumonija koju uzrokuje Pneumocystis jiroveci.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jiroveci pneumonia.
Mjerodavni su primjeri retinitis izazvan citomegalovirusom, generalizirane i/ili fokalne infekcije mikobakterijama i upala pluća prouzročena s Pneumocystis jiroveci s.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Relevantni primjeri su citomegalovirusni retinitis, opće i/ili fokalne mikobakterijske infekcije i pneumonija koju uzrokuje Pneumocystis jirovecii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii).
Odgovarajući primjeri su citomegalovirusni retinitis, opće i/ili lokalizirane infekcije mikobakterijama i upala pluća izazvana Pneumocystis jiroveci (prije poznata kao Pneumocystis carinii).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis carinii pneumonia.
Relevantni primjeri su retinitis uzrokovan citomegalovirusom, generalizirana i/ili žarišna infekcija mikobakterijama i upala pluća uzrokovana s Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis carinii pneumonia.
Relevantni primjeri uključuju citomegalovirusom izazvani retinitis, generalizirane i/ili fokalne infekcije mikobakterijama i pneumoniju izazvanu s Pneumocystis carinii.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis jiroveci pneumonia (formerly known as Pneumocystis carinii pneumonia).
Relevantni primjeri uključuju citomegalovirusni retinitis, generalizirane i/ili fokalne infekcije mikobakterijama i pneumoniju izazvanu s Pneumocystis jiroveci (nekad poznatog pod nazivom Pneumocystis carinii).
Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia.
Relevantni primjeri obuhvaćaju citomegalovirusni retinitis, generalizirane i/ili ţarišne mikobakterijske infekcije, te upalu pluća uzrokovanu s Pneumocystis jirovecii.
Relevant information (e.g. seriousness, severity, frequency, time to onset, reversibility of the AE as applicable) for the following safety concerns:
Relevantne informacije (npr. informacije o ozbiljnosti, težini, učestalosti, vremenu do nastupa i reverzibilnosti nuspojava, prema potrebi) za sljedeće sigurnosne probleme:
Relevant information on NEURACEQ as anβ-amyloid PET tracer, including the approved indication according to the SmPC, limitations of NEURACEQ use, interpretation errors, safety information and the results of clinical trials informing on the diagnostic use of NEURACEQ;
Značajne informacije o NEURACEQU kao obilježivaču β–amiloida pri snimanju PET-om, uključujući odobrene indikacije prema Sažetku opisa svojstava lijeka, ograničenja uporabe NEURACEQA, pogreške u tumačenju, sigurnosne informacije i rezultate kliničkih ispitivanja o primjeni NEURACEQA u dijagnostici;
Relevant information on the risk of bleeding
relevantne informacije o riziku od krvarenja
reliable method of contraception (see sections 4.4 and 4.6).
drugu pouzdanu metodu kontracepcije (vidjeti dijelove 4.4 i
Relief of oestrogen-deficiency symptoms and bleeding patterns
Ublažavanje simptoma nedostatka estrogena i obrazaca krvarenja
Relief of pain and inflammation associated with osteoarthritis: 6 months.
Ublažavanje bolova i upale povezane s osteoartritisom: 6 mjeseci.
Relief of post-operative pain following dehorning in calves.
Za ublaţavanje poslijeoperacijskih bolova nakon odroţnjavanja teladi.
Relieves heartburn
Ublažava žgaravicu
Relieves heartburn.
Ublažava žgaravicu.
Relistor 12 mg Injection Methylnaltrexone bromide SC
Relistor 12 mg injekcija metilnaltreksonbromid s.c.